PathoCare Holdings, the parent company of medical diagnostics innovator PathoCare, has announced it has received a private, third-party tendered offer for the secondary purchase of shares from existing shareholders, reflecting an implied company valuation of approximately $1.75 billion.
The transaction signals a continued evolution in PathoCare Holdings’ capital markets journey. The company previously completed a $150 million venture investment, acquisition, and recapitalization, followed by a third-party tender offer valuing the company at $500 million, which provided early secondary liquidity to select shareholders.
That $500 million valuation was independently confirmed by Lehrer Financial, a Houston-based economic and financial consulting firm with over 40 years of experience across industries including healthcare, banking, and emerging technologies.
“These transactions mark a sequential progression in external validation, institutional interest, and valuation benchmarks for the company,” the company noted.
To assess the new offer, PathoCare Holdings has engaged an independent financial advisory firm to conduct a formal fairness opinion and updated valuation analysis, examining the financial terms from a shareholder perspective using standard valuation methods, comparable company analysis, and market data.
“The receipt of a significant third-party tendered offer at this valuation level reflects growing institutional confidence in the long-term potential of our diagnostic platform,” said L. Mychal Jefferson, Chairman of PathoCare Holdings.
“Consistent with our prior transactions, the Board is proceeding with discipline and transparency by commissioning an independent fairness opinion before making any final determinations.”
